Shoshana Shendelman, PhD, President and Chief Executive Officer of Applied Therapeutics provides a brief overview of the orphan drug company.



As Dr Shendelman explains, Applied Therapeutics is a biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need. The Company’s lead drug candidate, govorestat, is an aldose reductase inhibitor (ARI). It is being developed to treat various rare metabolic disorders, including galactosemia, SORD deficiency, and PMM2-CDG. The Company is also developing AT-001, a novel potent ARI, for the treatment of diabetic cardiomyopathy. 

To learn more about these and other metabolic conditions, visit